Patents by Inventor Bernard Roizman

Bernard Roizman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220347243
    Abstract: Provided is a composition for treating tumors in a subject comprising a therapeutically effective amount of an exosome carrying CTLA4-targeting miRNA and a therapeutically effective amount of an oncolytic herpes simplex virus expressing an immunostimulatory agent or both an immunostimulatory agent and an anti-PD-1 antibody. Wherein an exo-motif operably links to the seed sequence of the CTLA4-targeting miRNA to enhance the packaging of the CTLA4-targeting miRNA into the exosome.
    Type: Application
    Filed: July 4, 2019
    Publication date: November 3, 2022
    Inventors: Xiaoqing Chen, Xusha Zhou, Bernard Roizman, Grace Guoying Zhou
  • Patent number: 11026990
    Abstract: Disclosed is a method for prophylaxis or treatment of infection of a virus, or for modulating innate immunity, in a subject comprising administering to the subject a therapeutically effective amount of a PUM1 inhibitor. A pharmaceutical composition comprising the PUM1 inhibitor is also disclosed.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: June 8, 2021
    Assignee: Shenzhen International Institute for Biomedical Research
    Inventors: Grace Zhou, Bernard Roizman, Yonghong Liu
  • Publication number: 20200164020
    Abstract: Disclosed is a method for prophylaxis or treatment of infection of a virus, or for modulating innate immunity, in a subject comprising administering to the subject a therapeutically effective amount of a PUM1 inhibitor. A pharmaceutical composition comprising the PUM1 inhibitor is also disclosed.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 28, 2020
    Inventors: Grace Zhou, Bernard Roizman, Yonghong Li
  • Patent number: 10561708
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 18, 2020
    Assignee: The University of Chicago
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Publication number: 20190381132
    Abstract: Disclosed is a method for treatment of a tumor in a subject comprising administering to the subject a therapeutically effective amount of an ATF3 activator. Use of an ATF3 activator in the preparation of a pharmaceutical composition for treatment of a tumor in a subject is also disclosed.
    Type: Application
    Filed: May 17, 2017
    Publication date: December 19, 2019
    Inventors: Minfeng Shu, Stephen Mallon, Ralph R. Weichselbaum, Bernard Roizman
  • Publication number: 20190071679
    Abstract: Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph Weichselbaum
  • Publication number: 20180256678
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Patent number: 9803006
    Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: October 31, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Guoying Zhou, Bernard Roizman
  • Publication number: 20170298362
    Abstract: Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 19, 2017
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph Weichselbaum
  • Patent number: 9790504
    Abstract: Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 17, 2017
    Assignee: The University of Chicago
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Patent number: 9669036
    Abstract: The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: June 6, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Bernard Roizman, Guoying Zhou, Te Du
  • Publication number: 20160367627
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more inhibitors of the JAK/STAT pathway which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 22, 2016
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Publication number: 20160222387
    Abstract: Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Application
    Filed: May 21, 2014
    Publication date: August 4, 2016
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Nikolai Khodarev, Ravi Sood, Bernard Roizman, Ralph R. Weichselbaum
  • Publication number: 20160175370
    Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells renders the HSV particles, particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
    Type: Application
    Filed: January 5, 2015
    Publication date: June 23, 2016
    Inventors: Guoying Zhou, Bernard Roizman
  • Publication number: 20160089376
    Abstract: The disclosure relates to methods of controlling the state of a virus (lytic or lysogenic) in an individual, such as a method of reactivating a latent virus in an individual, comprising administering one or more agents that modulates the activity of signal transducer and activator of transcription 3 (STAT3) or any of p300, CBP or p300/CBP. Also contemplated are methods further comprising administering an HDAC modulating agent, such as an HDAC inhibiting agent or an HDAC activating agent.
    Type: Application
    Filed: May 14, 2014
    Publication date: March 31, 2016
    Inventors: Bernard Roizman, Guoying Zhou, Te Du
  • Patent number: 8927251
    Abstract: The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a selected receptor, the HSV particles of the invention are useful for targeting cells that express the selected receptor, which itself may be a product of genetic engineering. The ability to selectively target cells render the HSV particles. particularly useful in selectively diagnosing, treating, and imaging cells bearing the selected binding pair member, such as a receptor. The invention also provides for polynucleotide-based therapy to cells bearing the selected binding pair member such as a receptor.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: January 6, 2015
    Assignee: The University of Chicago
    Inventors: Guoying Zhou, Bernard Roizman
  • Patent number: 8772261
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: July 8, 2014
    Assignee: Arch Development Corporation
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley
  • Patent number: 8318691
    Abstract: Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: November 27, 2012
    Assignees: Arch Development Corporation, UAB Research Foundation
    Inventors: Ralph R. Weichselbaum, Bernard Roizman, Richard J. Whitley
  • Publication number: 20110274661
    Abstract: The disclosure provides materials and methods for the treatment of cells exhibiting a cell proliferative disorder with a herpes simplex virus having a deficiency in the expression of active ICP34.5 and comprising an expression control element effective in modulating at least one component of the MEK pathway to ensure that infected cells are MEK+. Cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, are amenable to treatment using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.
    Type: Application
    Filed: August 7, 2009
    Publication date: November 10, 2011
    Applicant: The University of Chicago
    Inventors: Alice P. Poon, Ralph R. Weichselbaum, Bernard Roizman
  • Publication number: 20110200998
    Abstract: Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
    Type: Application
    Filed: February 8, 2011
    Publication date: August 18, 2011
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Ralph Weichselbaum, Bernard Roizman, Andy Minn, Nikolai Khodarev, Edwardine Labay